Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022GlobeNewsWire • 11/03/22
Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment ConferenceGlobeNewsWire • 09/20/22
Addex Therapeutics Ltd (ADXN) CEO Tim Dyer on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/18/22
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/18/22
Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/18/22
Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use DisordersGlobeNewsWire • 08/15/22
Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022GlobeNewsWire • 08/12/22
Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment RateGlobeNewsWire • 06/17/22
Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical StudyGlobeNewsWire • 05/27/22
Addex Announces Participation in the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/19/22
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/05/22
Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical StudyGlobeNewsWire • 04/13/22
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 03/29/22
Addex Therapeutics Limited (ADXN) CEO Tim Dyer on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/11/22